Global DTaP and Tdap Vaccines Market Growth 2025-2031
The global DTaP and Tdap Vaccines market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF?s total procurement.
Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.
The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%?85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?DTaP and Tdap Vaccines Industry Forecast? looks at past sales and reviews total world DTaP and Tdap Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected DTaP and Tdap Vaccines sales for 2025 through 2031. With DTaP and Tdap Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world DTaP and Tdap Vaccines industry.
This Insight Report provides a comprehensive analysis of the global DTaP and Tdap Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on DTaP and Tdap Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global DTaP and Tdap Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for DTaP and Tdap Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global DTaP and Tdap Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of DTaP and Tdap Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global DTaP and Tdap Vaccines market?
What factors are driving DTaP and Tdap Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do DTaP and Tdap Vaccines market opportunities vary by end market size?
How does DTaP and Tdap Vaccines break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF?s total procurement.
Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.
The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%?85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?DTaP and Tdap Vaccines Industry Forecast? looks at past sales and reviews total world DTaP and Tdap Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected DTaP and Tdap Vaccines sales for 2025 through 2031. With DTaP and Tdap Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world DTaP and Tdap Vaccines industry.
This Insight Report provides a comprehensive analysis of the global DTaP and Tdap Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on DTaP and Tdap Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global DTaP and Tdap Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for DTaP and Tdap Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global DTaP and Tdap Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of DTaP and Tdap Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- DTaP
- Td
- Tdap
- Adult
- Pediatric
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi Pasteur
- GlaxoSmithKline
- Protein Sciences Corporation
- Novartis AG
- Seqirus
- Merck Sharp & Dohme Corp
- Astellas Pharma US, Inc
- Pfizer Inc
- Johnson & Johnson
- Lanzhou Institute of Biological Products Co., Ltd
- AstraZeneca
- Emergent BioSolutions Inc
What is the 10-year outlook for the global DTaP and Tdap Vaccines market?
What factors are driving DTaP and Tdap Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do DTaP and Tdap Vaccines market opportunities vary by end market size?
How does DTaP and Tdap Vaccines break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global DTaP and Tdap Vaccines Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for DTaP and Tdap Vaccines by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for DTaP and Tdap Vaccines by Country/Region, 2020, 2024 & 2031
2.2 DTaP and Tdap Vaccines Segment by Type
2.2.1 DTaP
2.2.2 Td
2.2.3 Tdap
2.3 DTaP and Tdap Vaccines Sales by Type
2.3.1 Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
2.3.2 Global DTaP and Tdap Vaccines Revenue and Market Share by Type (2020-2025)
2.3.3 Global DTaP and Tdap Vaccines Sale Price by Type (2020-2025)
2.4 DTaP and Tdap Vaccines Segment by Application
2.4.1 Adult
2.4.2 Pediatric
2.5 DTaP and Tdap Vaccines Sales by Application
2.5.1 Global DTaP and Tdap Vaccines Sale Market Share by Application (2020-2025)
2.5.2 Global DTaP and Tdap Vaccines Revenue and Market Share by Application (2020-2025)
2.5.3 Global DTaP and Tdap Vaccines Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global DTaP and Tdap Vaccines Breakdown Data by Company
3.1.1 Global DTaP and Tdap Vaccines Annual Sales by Company (2020-2025)
3.1.2 Global DTaP and Tdap Vaccines Sales Market Share by Company (2020-2025)
3.2 Global DTaP and Tdap Vaccines Annual Revenue by Company (2020-2025)
3.2.1 Global DTaP and Tdap Vaccines Revenue by Company (2020-2025)
3.2.2 Global DTaP and Tdap Vaccines Revenue Market Share by Company (2020-2025)
3.3 Global DTaP and Tdap Vaccines Sale Price by Company
3.4 Key Manufacturers DTaP and Tdap Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers DTaP and Tdap Vaccines Product Location Distribution
3.4.2 Players DTaP and Tdap Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DTAP AND TDAP VACCINES BY GEOGRAPHIC REGION
4.1 World Historic DTaP and Tdap Vaccines Market Size by Geographic Region (2020-2025)
4.1.1 Global DTaP and Tdap Vaccines Annual Sales by Geographic Region (2020-2025)
4.1.2 Global DTaP and Tdap Vaccines Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic DTaP and Tdap Vaccines Market Size by Country/Region (2020-2025)
4.2.1 Global DTaP and Tdap Vaccines Annual Sales by Country/Region (2020-2025)
4.2.2 Global DTaP and Tdap Vaccines Annual Revenue by Country/Region (2020-2025)
4.3 Americas DTaP and Tdap Vaccines Sales Growth
4.4 APAC DTaP and Tdap Vaccines Sales Growth
4.5 Europe DTaP and Tdap Vaccines Sales Growth
4.6 Middle East & Africa DTaP and Tdap Vaccines Sales Growth
5 AMERICAS
5.1 Americas DTaP and Tdap Vaccines Sales by Country
5.1.1 Americas DTaP and Tdap Vaccines Sales by Country (2020-2025)
5.1.2 Americas DTaP and Tdap Vaccines Revenue by Country (2020-2025)
5.2 Americas DTaP and Tdap Vaccines Sales by Type (2020-2025)
5.3 Americas DTaP and Tdap Vaccines Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC DTaP and Tdap Vaccines Sales by Region
6.1.1 APAC DTaP and Tdap Vaccines Sales by Region (2020-2025)
6.1.2 APAC DTaP and Tdap Vaccines Revenue by Region (2020-2025)
6.2 APAC DTaP and Tdap Vaccines Sales by Type (2020-2025)
6.3 APAC DTaP and Tdap Vaccines Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe DTaP and Tdap Vaccines by Country
7.1.1 Europe DTaP and Tdap Vaccines Sales by Country (2020-2025)
7.1.2 Europe DTaP and Tdap Vaccines Revenue by Country (2020-2025)
7.2 Europe DTaP and Tdap Vaccines Sales by Type (2020-2025)
7.3 Europe DTaP and Tdap Vaccines Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa DTaP and Tdap Vaccines by Country
8.1.1 Middle East & Africa DTaP and Tdap Vaccines Sales by Country (2020-2025)
8.1.2 Middle East & Africa DTaP and Tdap Vaccines Revenue by Country (2020-2025)
8.2 Middle East & Africa DTaP and Tdap Vaccines Sales by Type (2020-2025)
8.3 Middle East & Africa DTaP and Tdap Vaccines Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of DTaP and Tdap Vaccines
10.3 Manufacturing Process Analysis of DTaP and Tdap Vaccines
10.4 Industry Chain Structure of DTaP and Tdap Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 DTaP and Tdap Vaccines Distributors
11.3 DTaP and Tdap Vaccines Customer
12 WORLD FORECAST REVIEW FOR DTAP AND TDAP VACCINES BY GEOGRAPHIC REGION
12.1 Global DTaP and Tdap Vaccines Market Size Forecast by Region
12.1.1 Global DTaP and Tdap Vaccines Forecast by Region (2026-2031)
12.1.2 Global DTaP and Tdap Vaccines Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global DTaP and Tdap Vaccines Forecast by Type (2026-2031)
12.7 Global DTaP and Tdap Vaccines Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi Pasteur
13.1.1 Sanofi Pasteur Company Information
13.1.2 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolios and Specifications
13.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sanofi Pasteur Main Business Overview
13.1.5 Sanofi Pasteur Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolios and Specifications
13.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Protein Sciences Corporation
13.3.1 Protein Sciences Corporation Company Information
13.3.2 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolios and Specifications
13.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Protein Sciences Corporation Main Business Overview
13.3.5 Protein Sciences Corporation Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG DTaP and Tdap Vaccines Product Portfolios and Specifications
13.4.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Seqirus
13.5.1 Seqirus Company Information
13.5.2 Seqirus DTaP and Tdap Vaccines Product Portfolios and Specifications
13.5.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Seqirus Main Business Overview
13.5.5 Seqirus Latest Developments
13.6 Merck Sharp & Dohme Corp
13.6.1 Merck Sharp & Dohme Corp Company Information
13.6.2 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolios and Specifications
13.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Merck Sharp & Dohme Corp Main Business Overview
13.6.5 Merck Sharp & Dohme Corp Latest Developments
13.7 Astellas Pharma US, Inc
13.7.1 Astellas Pharma US, Inc Company Information
13.7.2 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
13.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Astellas Pharma US, Inc Main Business Overview
13.7.5 Astellas Pharma US, Inc Latest Developments
13.8 Pfizer Inc
13.8.1 Pfizer Inc Company Information
13.8.2 Pfizer Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
13.8.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Pfizer Inc Main Business Overview
13.8.5 Pfizer Inc Latest Developments
13.9 Johnson & Johnson
13.9.1 Johnson & Johnson Company Information
13.9.2 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolios and Specifications
13.9.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Johnson & Johnson Main Business Overview
13.9.5 Johnson & Johnson Latest Developments
13.10 Lanzhou Institute of Biological Products Co., Ltd
13.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
13.10.2 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolios and Specifications
13.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Lanzhou Institute of Biological Products Co., Ltd Main Business Overview
13.10.5 Lanzhou Institute of Biological Products Co., Ltd Latest Developments
13.11 AstraZeneca
13.11.1 AstraZeneca Company Information
13.11.2 AstraZeneca DTaP and Tdap Vaccines Product Portfolios and Specifications
13.11.3 AstraZeneca DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 AstraZeneca Main Business Overview
13.11.5 AstraZeneca Latest Developments
13.12 Emergent BioSolutions Inc
13.12.1 Emergent BioSolutions Inc Company Information
13.12.2 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
13.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Emergent BioSolutions Inc Main Business Overview
13.12.5 Emergent BioSolutions Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global DTaP and Tdap Vaccines Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for DTaP and Tdap Vaccines by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for DTaP and Tdap Vaccines by Country/Region, 2020, 2024 & 2031
2.2 DTaP and Tdap Vaccines Segment by Type
2.2.1 DTaP
2.2.2 Td
2.2.3 Tdap
2.3 DTaP and Tdap Vaccines Sales by Type
2.3.1 Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
2.3.2 Global DTaP and Tdap Vaccines Revenue and Market Share by Type (2020-2025)
2.3.3 Global DTaP and Tdap Vaccines Sale Price by Type (2020-2025)
2.4 DTaP and Tdap Vaccines Segment by Application
2.4.1 Adult
2.4.2 Pediatric
2.5 DTaP and Tdap Vaccines Sales by Application
2.5.1 Global DTaP and Tdap Vaccines Sale Market Share by Application (2020-2025)
2.5.2 Global DTaP and Tdap Vaccines Revenue and Market Share by Application (2020-2025)
2.5.3 Global DTaP and Tdap Vaccines Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global DTaP and Tdap Vaccines Breakdown Data by Company
3.1.1 Global DTaP and Tdap Vaccines Annual Sales by Company (2020-2025)
3.1.2 Global DTaP and Tdap Vaccines Sales Market Share by Company (2020-2025)
3.2 Global DTaP and Tdap Vaccines Annual Revenue by Company (2020-2025)
3.2.1 Global DTaP and Tdap Vaccines Revenue by Company (2020-2025)
3.2.2 Global DTaP and Tdap Vaccines Revenue Market Share by Company (2020-2025)
3.3 Global DTaP and Tdap Vaccines Sale Price by Company
3.4 Key Manufacturers DTaP and Tdap Vaccines Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers DTaP and Tdap Vaccines Product Location Distribution
3.4.2 Players DTaP and Tdap Vaccines Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DTAP AND TDAP VACCINES BY GEOGRAPHIC REGION
4.1 World Historic DTaP and Tdap Vaccines Market Size by Geographic Region (2020-2025)
4.1.1 Global DTaP and Tdap Vaccines Annual Sales by Geographic Region (2020-2025)
4.1.2 Global DTaP and Tdap Vaccines Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic DTaP and Tdap Vaccines Market Size by Country/Region (2020-2025)
4.2.1 Global DTaP and Tdap Vaccines Annual Sales by Country/Region (2020-2025)
4.2.2 Global DTaP and Tdap Vaccines Annual Revenue by Country/Region (2020-2025)
4.3 Americas DTaP and Tdap Vaccines Sales Growth
4.4 APAC DTaP and Tdap Vaccines Sales Growth
4.5 Europe DTaP and Tdap Vaccines Sales Growth
4.6 Middle East & Africa DTaP and Tdap Vaccines Sales Growth
5 AMERICAS
5.1 Americas DTaP and Tdap Vaccines Sales by Country
5.1.1 Americas DTaP and Tdap Vaccines Sales by Country (2020-2025)
5.1.2 Americas DTaP and Tdap Vaccines Revenue by Country (2020-2025)
5.2 Americas DTaP and Tdap Vaccines Sales by Type (2020-2025)
5.3 Americas DTaP and Tdap Vaccines Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC DTaP and Tdap Vaccines Sales by Region
6.1.1 APAC DTaP and Tdap Vaccines Sales by Region (2020-2025)
6.1.2 APAC DTaP and Tdap Vaccines Revenue by Region (2020-2025)
6.2 APAC DTaP and Tdap Vaccines Sales by Type (2020-2025)
6.3 APAC DTaP and Tdap Vaccines Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe DTaP and Tdap Vaccines by Country
7.1.1 Europe DTaP and Tdap Vaccines Sales by Country (2020-2025)
7.1.2 Europe DTaP and Tdap Vaccines Revenue by Country (2020-2025)
7.2 Europe DTaP and Tdap Vaccines Sales by Type (2020-2025)
7.3 Europe DTaP and Tdap Vaccines Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa DTaP and Tdap Vaccines by Country
8.1.1 Middle East & Africa DTaP and Tdap Vaccines Sales by Country (2020-2025)
8.1.2 Middle East & Africa DTaP and Tdap Vaccines Revenue by Country (2020-2025)
8.2 Middle East & Africa DTaP and Tdap Vaccines Sales by Type (2020-2025)
8.3 Middle East & Africa DTaP and Tdap Vaccines Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of DTaP and Tdap Vaccines
10.3 Manufacturing Process Analysis of DTaP and Tdap Vaccines
10.4 Industry Chain Structure of DTaP and Tdap Vaccines
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 DTaP and Tdap Vaccines Distributors
11.3 DTaP and Tdap Vaccines Customer
12 WORLD FORECAST REVIEW FOR DTAP AND TDAP VACCINES BY GEOGRAPHIC REGION
12.1 Global DTaP and Tdap Vaccines Market Size Forecast by Region
12.1.1 Global DTaP and Tdap Vaccines Forecast by Region (2026-2031)
12.1.2 Global DTaP and Tdap Vaccines Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global DTaP and Tdap Vaccines Forecast by Type (2026-2031)
12.7 Global DTaP and Tdap Vaccines Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi Pasteur
13.1.1 Sanofi Pasteur Company Information
13.1.2 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolios and Specifications
13.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Sanofi Pasteur Main Business Overview
13.1.5 Sanofi Pasteur Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolios and Specifications
13.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Protein Sciences Corporation
13.3.1 Protein Sciences Corporation Company Information
13.3.2 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolios and Specifications
13.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Protein Sciences Corporation Main Business Overview
13.3.5 Protein Sciences Corporation Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG DTaP and Tdap Vaccines Product Portfolios and Specifications
13.4.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Seqirus
13.5.1 Seqirus Company Information
13.5.2 Seqirus DTaP and Tdap Vaccines Product Portfolios and Specifications
13.5.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Seqirus Main Business Overview
13.5.5 Seqirus Latest Developments
13.6 Merck Sharp & Dohme Corp
13.6.1 Merck Sharp & Dohme Corp Company Information
13.6.2 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolios and Specifications
13.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Merck Sharp & Dohme Corp Main Business Overview
13.6.5 Merck Sharp & Dohme Corp Latest Developments
13.7 Astellas Pharma US, Inc
13.7.1 Astellas Pharma US, Inc Company Information
13.7.2 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
13.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Astellas Pharma US, Inc Main Business Overview
13.7.5 Astellas Pharma US, Inc Latest Developments
13.8 Pfizer Inc
13.8.1 Pfizer Inc Company Information
13.8.2 Pfizer Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
13.8.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Pfizer Inc Main Business Overview
13.8.5 Pfizer Inc Latest Developments
13.9 Johnson & Johnson
13.9.1 Johnson & Johnson Company Information
13.9.2 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolios and Specifications
13.9.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Johnson & Johnson Main Business Overview
13.9.5 Johnson & Johnson Latest Developments
13.10 Lanzhou Institute of Biological Products Co., Ltd
13.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
13.10.2 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolios and Specifications
13.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Lanzhou Institute of Biological Products Co., Ltd Main Business Overview
13.10.5 Lanzhou Institute of Biological Products Co., Ltd Latest Developments
13.11 AstraZeneca
13.11.1 AstraZeneca Company Information
13.11.2 AstraZeneca DTaP and Tdap Vaccines Product Portfolios and Specifications
13.11.3 AstraZeneca DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 AstraZeneca Main Business Overview
13.11.5 AstraZeneca Latest Developments
13.12 Emergent BioSolutions Inc
13.12.1 Emergent BioSolutions Inc Company Information
13.12.2 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
13.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Emergent BioSolutions Inc Main Business Overview
13.12.5 Emergent BioSolutions Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. DTaP and Tdap Vaccines Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. DTaP and Tdap Vaccines Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of DTaP
Table 4. Major Players of Td
Table 5. Major Players of Tdap
Table 6. Global DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 7. Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Table 8. Global DTaP and Tdap Vaccines Revenue by Type (2020-2025) & ($ million)
Table 9. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2020-2025)
Table 10. Global DTaP and Tdap Vaccines Sale Price by Type (2020-2025) & (USD/Unit)
Table 11. Global DTaP and Tdap Vaccines Sale by Application (2020-2025) & (K Units)
Table 12. Global DTaP and Tdap Vaccines Sale Market Share by Application (2020-2025)
Table 13. Global DTaP and Tdap Vaccines Revenue by Application (2020-2025) & ($ million)
Table 14. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2020-2025)
Table 15. Global DTaP and Tdap Vaccines Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global DTaP and Tdap Vaccines Sales by Company (2020-2025) & (K Units)
Table 17. Global DTaP and Tdap Vaccines Sales Market Share by Company (2020-2025)
Table 18. Global DTaP and Tdap Vaccines Revenue by Company (2020-2025) & ($ millions)
Table 19. Global DTaP and Tdap Vaccines Revenue Market Share by Company (2020-2025)
Table 20. Global DTaP and Tdap Vaccines Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers DTaP and Tdap Vaccines Producing Area Distribution and Sales Area
Table 22. Players DTaP and Tdap Vaccines Products Offered
Table 23. DTaP and Tdap Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global DTaP and Tdap Vaccines Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global DTaP and Tdap Vaccines Sales Market Share Geographic Region (2020-2025)
Table 28. Global DTaP and Tdap Vaccines Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global DTaP and Tdap Vaccines Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global DTaP and Tdap Vaccines Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global DTaP and Tdap Vaccines Sales Market Share by Country/Region (2020-2025)
Table 32. Global DTaP and Tdap Vaccines Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global DTaP and Tdap Vaccines Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)
Table 35. Americas DTaP and Tdap Vaccines Sales Market Share by Country (2020-2025)
Table 36. Americas DTaP and Tdap Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 38. Americas DTaP and Tdap Vaccines Sales by Application (2020-2025) & (K Units)
Table 39. APAC DTaP and Tdap Vaccines Sales by Region (2020-2025) & (K Units)
Table 40. APAC DTaP and Tdap Vaccines Sales Market Share by Region (2020-2025)
Table 41. APAC DTaP and Tdap Vaccines Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 43. APAC DTaP and Tdap Vaccines Sales by Application (2020-2025) & (K Units)
Table 44. Europe DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)
Table 45. Europe DTaP and Tdap Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 47. Europe DTaP and Tdap Vaccines Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa DTaP and Tdap Vaccines Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of DTaP and Tdap Vaccines
Table 53. Key Market Challenges & Risks of DTaP and Tdap Vaccines
Table 54. Key Industry Trends of DTaP and Tdap Vaccines
Table 55. DTaP and Tdap Vaccines Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. DTaP and Tdap Vaccines Distributors List
Table 58. DTaP and Tdap Vaccines Customer List
Table 59. Global DTaP and Tdap Vaccines Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global DTaP and Tdap Vaccines Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas DTaP and Tdap Vaccines Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas DTaP and Tdap Vaccines Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC DTaP and Tdap Vaccines Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC DTaP and Tdap Vaccines Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe DTaP and Tdap Vaccines Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe DTaP and Tdap Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa DTaP and Tdap Vaccines Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa DTaP and Tdap Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global DTaP and Tdap Vaccines Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global DTaP and Tdap Vaccines Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global DTaP and Tdap Vaccines Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global DTaP and Tdap Vaccines Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Sanofi Pasteur Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 74. Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 75. Sanofi Pasteur DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Sanofi Pasteur Main Business
Table 77. Sanofi Pasteur Latest Developments
Table 78. GlaxoSmithKline Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 80. GlaxoSmithKline DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. GlaxoSmithKline Main Business
Table 82. GlaxoSmithKline Latest Developments
Table 83. Protein Sciences Corporation Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 85. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Protein Sciences Corporation Main Business
Table 87. Protein Sciences Corporation Latest Developments
Table 88. Novartis AG Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. Novartis AG DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 90. Novartis AG DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Novartis AG Main Business
Table 92. Novartis AG Latest Developments
Table 93. Seqirus Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Seqirus DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 95. Seqirus DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Seqirus Main Business
Table 97. Seqirus Latest Developments
Table 98. Merck Sharp & Dohme Corp Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 100. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Merck Sharp & Dohme Corp Main Business
Table 102. Merck Sharp & Dohme Corp Latest Developments
Table 103. Astellas Pharma US, Inc Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 105. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. Astellas Pharma US, Inc Main Business
Table 107. Astellas Pharma US, Inc Latest Developments
Table 108. Pfizer Inc Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 110. Pfizer Inc DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Pfizer Inc Main Business
Table 112. Pfizer Inc Latest Developments
Table 113. Johnson & Johnson Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. Johnson & Johnson DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 115. Johnson & Johnson DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 116. Johnson & Johnson Main Business
Table 117. Johnson & Johnson Latest Developments
Table 118. Lanzhou Institute of Biological Products Co., Ltd Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 120. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 121. Lanzhou Institute of Biological Products Co., Ltd Main Business
Table 122. Lanzhou Institute of Biological Products Co., Ltd Latest Developments
Table 123. AstraZeneca Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. AstraZeneca DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 125. AstraZeneca DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 126. AstraZeneca Main Business
Table 127. AstraZeneca Latest Developments
Table 128. Emergent BioSolutions Inc Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 129. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 130. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 131. Emergent BioSolutions Inc Main Business
Table 132. Emergent BioSolutions Inc Latest Developments
Table 1. DTaP and Tdap Vaccines Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. DTaP and Tdap Vaccines Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of DTaP
Table 4. Major Players of Td
Table 5. Major Players of Tdap
Table 6. Global DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 7. Global DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Table 8. Global DTaP and Tdap Vaccines Revenue by Type (2020-2025) & ($ million)
Table 9. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2020-2025)
Table 10. Global DTaP and Tdap Vaccines Sale Price by Type (2020-2025) & (USD/Unit)
Table 11. Global DTaP and Tdap Vaccines Sale by Application (2020-2025) & (K Units)
Table 12. Global DTaP and Tdap Vaccines Sale Market Share by Application (2020-2025)
Table 13. Global DTaP and Tdap Vaccines Revenue by Application (2020-2025) & ($ million)
Table 14. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2020-2025)
Table 15. Global DTaP and Tdap Vaccines Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global DTaP and Tdap Vaccines Sales by Company (2020-2025) & (K Units)
Table 17. Global DTaP and Tdap Vaccines Sales Market Share by Company (2020-2025)
Table 18. Global DTaP and Tdap Vaccines Revenue by Company (2020-2025) & ($ millions)
Table 19. Global DTaP and Tdap Vaccines Revenue Market Share by Company (2020-2025)
Table 20. Global DTaP and Tdap Vaccines Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers DTaP and Tdap Vaccines Producing Area Distribution and Sales Area
Table 22. Players DTaP and Tdap Vaccines Products Offered
Table 23. DTaP and Tdap Vaccines Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global DTaP and Tdap Vaccines Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global DTaP and Tdap Vaccines Sales Market Share Geographic Region (2020-2025)
Table 28. Global DTaP and Tdap Vaccines Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global DTaP and Tdap Vaccines Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global DTaP and Tdap Vaccines Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global DTaP and Tdap Vaccines Sales Market Share by Country/Region (2020-2025)
Table 32. Global DTaP and Tdap Vaccines Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global DTaP and Tdap Vaccines Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)
Table 35. Americas DTaP and Tdap Vaccines Sales Market Share by Country (2020-2025)
Table 36. Americas DTaP and Tdap Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 38. Americas DTaP and Tdap Vaccines Sales by Application (2020-2025) & (K Units)
Table 39. APAC DTaP and Tdap Vaccines Sales by Region (2020-2025) & (K Units)
Table 40. APAC DTaP and Tdap Vaccines Sales Market Share by Region (2020-2025)
Table 41. APAC DTaP and Tdap Vaccines Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 43. APAC DTaP and Tdap Vaccines Sales by Application (2020-2025) & (K Units)
Table 44. Europe DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)
Table 45. Europe DTaP and Tdap Vaccines Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 47. Europe DTaP and Tdap Vaccines Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa DTaP and Tdap Vaccines Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa DTaP and Tdap Vaccines Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa DTaP and Tdap Vaccines Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of DTaP and Tdap Vaccines
Table 53. Key Market Challenges & Risks of DTaP and Tdap Vaccines
Table 54. Key Industry Trends of DTaP and Tdap Vaccines
Table 55. DTaP and Tdap Vaccines Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. DTaP and Tdap Vaccines Distributors List
Table 58. DTaP and Tdap Vaccines Customer List
Table 59. Global DTaP and Tdap Vaccines Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global DTaP and Tdap Vaccines Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas DTaP and Tdap Vaccines Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas DTaP and Tdap Vaccines Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC DTaP and Tdap Vaccines Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC DTaP and Tdap Vaccines Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe DTaP and Tdap Vaccines Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe DTaP and Tdap Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa DTaP and Tdap Vaccines Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa DTaP and Tdap Vaccines Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global DTaP and Tdap Vaccines Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global DTaP and Tdap Vaccines Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global DTaP and Tdap Vaccines Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global DTaP and Tdap Vaccines Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Sanofi Pasteur Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 74. Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 75. Sanofi Pasteur DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Sanofi Pasteur Main Business
Table 77. Sanofi Pasteur Latest Developments
Table 78. GlaxoSmithKline Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 79. GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 80. GlaxoSmithKline DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. GlaxoSmithKline Main Business
Table 82. GlaxoSmithKline Latest Developments
Table 83. Protein Sciences Corporation Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 84. Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 85. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Protein Sciences Corporation Main Business
Table 87. Protein Sciences Corporation Latest Developments
Table 88. Novartis AG Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 89. Novartis AG DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 90. Novartis AG DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. Novartis AG Main Business
Table 92. Novartis AG Latest Developments
Table 93. Seqirus Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 94. Seqirus DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 95. Seqirus DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Seqirus Main Business
Table 97. Seqirus Latest Developments
Table 98. Merck Sharp & Dohme Corp Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 99. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 100. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. Merck Sharp & Dohme Corp Main Business
Table 102. Merck Sharp & Dohme Corp Latest Developments
Table 103. Astellas Pharma US, Inc Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 104. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 105. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. Astellas Pharma US, Inc Main Business
Table 107. Astellas Pharma US, Inc Latest Developments
Table 108. Pfizer Inc Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 110. Pfizer Inc DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Pfizer Inc Main Business
Table 112. Pfizer Inc Latest Developments
Table 113. Johnson & Johnson Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 114. Johnson & Johnson DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 115. Johnson & Johnson DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 116. Johnson & Johnson Main Business
Table 117. Johnson & Johnson Latest Developments
Table 118. Lanzhou Institute of Biological Products Co., Ltd Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 119. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 120. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 121. Lanzhou Institute of Biological Products Co., Ltd Main Business
Table 122. Lanzhou Institute of Biological Products Co., Ltd Latest Developments
Table 123. AstraZeneca Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 124. AstraZeneca DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 125. AstraZeneca DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 126. AstraZeneca Main Business
Table 127. AstraZeneca Latest Developments
Table 128. Emergent BioSolutions Inc Basic Information, DTaP and Tdap Vaccines Manufacturing Base, Sales Area and Its Competitors
Table 129. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolios and Specifications
Table 130. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 131. Emergent BioSolutions Inc Main Business
Table 132. Emergent BioSolutions Inc Latest Developments
LIST OF FIGURES
Figure 1. Picture of DTaP and Tdap Vaccines
Figure 2. DTaP and Tdap Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global DTaP and Tdap Vaccines Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global DTaP and Tdap Vaccines Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. DTaP and Tdap Vaccines Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. DTaP and Tdap Vaccines Sales Market Share by Country/Region (2024)
Figure 10. DTaP and Tdap Vaccines Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of DTaP
Figure 12. Product Picture of Td
Figure 13. Product Picture of Tdap
Figure 14. Global DTaP and Tdap Vaccines Sales Market Share by Type in 2025
Figure 15. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2020-2025)
Figure 16. DTaP and Tdap Vaccines Consumed in Adult
Figure 17. Global DTaP and Tdap Vaccines Market: Adult (2020-2025) & (K Units)
Figure 18. DTaP and Tdap Vaccines Consumed in Pediatric
Figure 19. Global DTaP and Tdap Vaccines Market: Pediatric (2020-2025) & (K Units)
Figure 20. Global DTaP and Tdap Vaccines Sale Market Share by Application (2024)
Figure 21. Global DTaP and Tdap Vaccines Revenue Market Share by Application in 2025
Figure 22. DTaP and Tdap Vaccines Sales by Company in 2025 (K Units)
Figure 23. Global DTaP and Tdap Vaccines Sales Market Share by Company in 2025
Figure 24. DTaP and Tdap Vaccines Revenue by Company in 2025 ($ millions)
Figure 25. Global DTaP and Tdap Vaccines Revenue Market Share by Company in 2025
Figure 26. Global DTaP and Tdap Vaccines Sales Market Share by Geographic Region (2020-2025)
Figure 27. Global DTaP and Tdap Vaccines Revenue Market Share by Geographic Region in 2025
Figure 28. Americas DTaP and Tdap Vaccines Sales 2020-2025 (K Units)
Figure 29. Americas DTaP and Tdap Vaccines Revenue 2020-2025 ($ millions)
Figure 30. APAC DTaP and Tdap Vaccines Sales 2020-2025 (K Units)
Figure 31. APAC DTaP and Tdap Vaccines Revenue 2020-2025 ($ millions)
Figure 32. Europe DTaP and Tdap Vaccines Sales 2020-2025 (K Units)
Figure 33. Europe DTaP and Tdap Vaccines Revenue 2020-2025 ($ millions)
Figure 34. Middle East & Africa DTaP and Tdap Vaccines Sales 2020-2025 (K Units)
Figure 35. Middle East & Africa DTaP and Tdap Vaccines Revenue 2020-2025 ($ millions)
Figure 36. Americas DTaP and Tdap Vaccines Sales Market Share by Country in 2025
Figure 37. Americas DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2025)
Figure 38. Americas DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Figure 39. Americas DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)
Figure 40. United States DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 41. Canada DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 42. Mexico DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 43. Brazil DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 44. APAC DTaP and Tdap Vaccines Sales Market Share by Region in 2025
Figure 45. APAC DTaP and Tdap Vaccines Revenue Market Share by Region (2020-2025)
Figure 46. APAC DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Figure 47. APAC DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)
Figure 48. China DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 49. Japan DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 50. South Korea DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 51. Southeast Asia DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 52. India DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 53. Australia DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 54. China Taiwan DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 55. Europe DTaP and Tdap Vaccines Sales Market Share by Country in 2025
Figure 56. Europe DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2025)
Figure 57. Europe DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Figure 58. Europe DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)
Figure 59. Germany DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 60. France DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 61. UK DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 62. Italy DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 63. Russia DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 64. Middle East & Africa DTaP and Tdap Vaccines Sales Market Share by Country (2020-2025)
Figure 65. Middle East & Africa DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Figure 66. Middle East & Africa DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)
Figure 67. Egypt DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 68. South Africa DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 69. Israel DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 70. Turkey DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 71. GCC Countries DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of DTaP and Tdap Vaccines in 2025
Figure 73. Manufacturing Process Analysis of DTaP and Tdap Vaccines
Figure 74. Industry Chain Structure of DTaP and Tdap Vaccines
Figure 75. Channels of Distribution
Figure 76. Global DTaP and Tdap Vaccines Sales Market Forecast by Region (2026-2031)
Figure 77. Global DTaP and Tdap Vaccines Revenue Market Share Forecast by Region (2026-2031)
Figure 78. Global DTaP and Tdap Vaccines Sales Market Share Forecast by Type (2026-2031)
Figure 79. Global DTaP and Tdap Vaccines Revenue Market Share Forecast by Type (2026-2031)
Figure 80. Global DTaP and Tdap Vaccines Sales Market Share Forecast by Application (2026-2031)
Figure 81. Global DTaP and Tdap Vaccines Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of DTaP and Tdap Vaccines
Figure 2. DTaP and Tdap Vaccines Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global DTaP and Tdap Vaccines Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global DTaP and Tdap Vaccines Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. DTaP and Tdap Vaccines Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. DTaP and Tdap Vaccines Sales Market Share by Country/Region (2024)
Figure 10. DTaP and Tdap Vaccines Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of DTaP
Figure 12. Product Picture of Td
Figure 13. Product Picture of Tdap
Figure 14. Global DTaP and Tdap Vaccines Sales Market Share by Type in 2025
Figure 15. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2020-2025)
Figure 16. DTaP and Tdap Vaccines Consumed in Adult
Figure 17. Global DTaP and Tdap Vaccines Market: Adult (2020-2025) & (K Units)
Figure 18. DTaP and Tdap Vaccines Consumed in Pediatric
Figure 19. Global DTaP and Tdap Vaccines Market: Pediatric (2020-2025) & (K Units)
Figure 20. Global DTaP and Tdap Vaccines Sale Market Share by Application (2024)
Figure 21. Global DTaP and Tdap Vaccines Revenue Market Share by Application in 2025
Figure 22. DTaP and Tdap Vaccines Sales by Company in 2025 (K Units)
Figure 23. Global DTaP and Tdap Vaccines Sales Market Share by Company in 2025
Figure 24. DTaP and Tdap Vaccines Revenue by Company in 2025 ($ millions)
Figure 25. Global DTaP and Tdap Vaccines Revenue Market Share by Company in 2025
Figure 26. Global DTaP and Tdap Vaccines Sales Market Share by Geographic Region (2020-2025)
Figure 27. Global DTaP and Tdap Vaccines Revenue Market Share by Geographic Region in 2025
Figure 28. Americas DTaP and Tdap Vaccines Sales 2020-2025 (K Units)
Figure 29. Americas DTaP and Tdap Vaccines Revenue 2020-2025 ($ millions)
Figure 30. APAC DTaP and Tdap Vaccines Sales 2020-2025 (K Units)
Figure 31. APAC DTaP and Tdap Vaccines Revenue 2020-2025 ($ millions)
Figure 32. Europe DTaP and Tdap Vaccines Sales 2020-2025 (K Units)
Figure 33. Europe DTaP and Tdap Vaccines Revenue 2020-2025 ($ millions)
Figure 34. Middle East & Africa DTaP and Tdap Vaccines Sales 2020-2025 (K Units)
Figure 35. Middle East & Africa DTaP and Tdap Vaccines Revenue 2020-2025 ($ millions)
Figure 36. Americas DTaP and Tdap Vaccines Sales Market Share by Country in 2025
Figure 37. Americas DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2025)
Figure 38. Americas DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Figure 39. Americas DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)
Figure 40. United States DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 41. Canada DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 42. Mexico DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 43. Brazil DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 44. APAC DTaP and Tdap Vaccines Sales Market Share by Region in 2025
Figure 45. APAC DTaP and Tdap Vaccines Revenue Market Share by Region (2020-2025)
Figure 46. APAC DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Figure 47. APAC DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)
Figure 48. China DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 49. Japan DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 50. South Korea DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 51. Southeast Asia DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 52. India DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 53. Australia DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 54. China Taiwan DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 55. Europe DTaP and Tdap Vaccines Sales Market Share by Country in 2025
Figure 56. Europe DTaP and Tdap Vaccines Revenue Market Share by Country (2020-2025)
Figure 57. Europe DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Figure 58. Europe DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)
Figure 59. Germany DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 60. France DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 61. UK DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 62. Italy DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 63. Russia DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 64. Middle East & Africa DTaP and Tdap Vaccines Sales Market Share by Country (2020-2025)
Figure 65. Middle East & Africa DTaP and Tdap Vaccines Sales Market Share by Type (2020-2025)
Figure 66. Middle East & Africa DTaP and Tdap Vaccines Sales Market Share by Application (2020-2025)
Figure 67. Egypt DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 68. South Africa DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 69. Israel DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 70. Turkey DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 71. GCC Countries DTaP and Tdap Vaccines Revenue Growth 2020-2025 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of DTaP and Tdap Vaccines in 2025
Figure 73. Manufacturing Process Analysis of DTaP and Tdap Vaccines
Figure 74. Industry Chain Structure of DTaP and Tdap Vaccines
Figure 75. Channels of Distribution
Figure 76. Global DTaP and Tdap Vaccines Sales Market Forecast by Region (2026-2031)
Figure 77. Global DTaP and Tdap Vaccines Revenue Market Share Forecast by Region (2026-2031)
Figure 78. Global DTaP and Tdap Vaccines Sales Market Share Forecast by Type (2026-2031)
Figure 79. Global DTaP and Tdap Vaccines Revenue Market Share Forecast by Type (2026-2031)
Figure 80. Global DTaP and Tdap Vaccines Sales Market Share Forecast by Application (2026-2031)
Figure 81. Global DTaP and Tdap Vaccines Revenue Market Share Forecast by Application (2026-2031)
More Publications
Global Radiographic Testing Market Growth 2024-2030
US$ 3,660.00
February 2024
117 pages
Global Lentinan Market Growth 2025-2031
US$ 3,660.00
March 2025
99 pages
Global Dental Chair Market Growth 2025-2031
US$ 3,660.00
March 2025
144 pages
